A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Academic Article uri icon

Overview

abstract

  • Improved vaccines and antiviral agents that provide better, broader protection against seasonal and emerging influenza viruses are needed. The viral surface glycoprotein hemagglutinin (HA) is a primary target for the development of universal influenza vaccines and therapeutic antibodies. The other major surface antigen, neuraminidase (NA), has been less well studied as a potential target and fewer broadly reactive anti-NA antibodies have been identified. In this study, we isolate three human monoclonal antibodies that recognize NA from A/H1N1 subtypes, and find that one of them, clone DA03E17, binds to the NA of A/H3N2, A/H5N1, A/H7N9, B/Ancestral-lineage, B/Yamagata-lineage, and B/Victoria-lineage viruses. DA03E17 inhibits the neuraminidase activity by direct binding to the enzyme active site, and provides in vitro and in vivo protection against infection with several types of influenza virus. This clone could, therefore, be useful as a broadly protective therapeutic agent. Moreover, the neutralizing epitope of DA03E17 could be useful in the development of an NA-based universal influenza vaccine.

publication date

  • November 3, 2022

Research

keywords

  • Herpesvirus 1, Cercopithecine
  • Influenza A Virus, H1N1 Subtype
  • Influenza A Virus, H5N1 Subtype
  • Influenza A Virus, H7N9 Subtype
  • Influenza Vaccines
  • Influenza, Human
  • Orthomyxoviridae Infections

Identity

PubMed Central ID

  • PMC9632566

Scopus Document Identifier

  • 85141148291

Digital Object Identifier (DOI)

  • 10.1038/s41467-022-34521-0

PubMed ID

  • 36329075

Additional Document Info

volume

  • 13

issue

  • 1